Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6194728 | 0.92 | OGA (0.50) | ALDH1A1OGAPIM1SRD5A2MAPT | |
| SCHEMBL20332701 | 0.84 | NR1H2 (0.48) | ALDH1A1OGAPIM1MAPT | |
| SCHEMBL14030458 | 0.80 | OGA (0.52) | ALDH1A1OGAPIM1MAPTNPC1 | |
| SCHEMBL4662026 | 0.79 | ALDH1A1 (0.61) | ALDH1A1OGAPIM1MAPTNPC1 | |
| SCHEMBL23887638 | 0.79 | SRD5A2 (0.43) | SRD5A2 | |
| SCHEMBL23887668 | 0.79 | SRD5A2 (0.43) | SRD5A2NPC1RAB9AGPR183HPGD | |
| SCHEMBL1602307 | 0.78 | OGA (0.46) | ALDH1A1OGAPIM1SRD5A2MAPT | |
| SCHEMBL14720729 | 0.77 | SRD5A2 (0.47) | ALDH1A1SRD5A2NPC1RAB9AHPGD | |
| SCHEMBL18170306 | 0.77 | ALDH1A1 (0.47) | ALDH1A1OGAPIM1MAPTNPC1 | |
| SCHEMBL6392680 | 0.76 | SRD5A1 (0.50) | ALDH1A1SRD5A2RAB9ATDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087314-A1 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2020-03-19 | — | — | US | disclosed |
| EP-3558947-A2 | HISTONE DEACETYLASE INHIBITORS | BioMarin Pharmaceutical Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119362-A2 | HISTONE DEACETYLASE INHIBITORS | BIOMARIN PHARMACEUTICALS INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087314-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | ALDH1A1 1150/4885OGA 1204/4885PIM1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.